论文部分内容阅读
目的探讨联合检测甲胎蛋白(AFP)、α-L-岩藻糖苷酶(AFU)及#2-微球蛋白(#2-MG)在原发性肝癌诊断中的价值。方法分别采用电化学发光法、速率法和免疫透射比浊法检测78例原发性肝癌患者、45例肝硬化患者及50例健康者血清中AFP、AFU和#2-MG的含量。结果 AFP、AFU和#2-MG在原发性肝癌患者血清中的浓度均高于肝硬化组及正常对照组(P<0.01),且原发性肝癌组中的AFP、AFU和#2-MG阳性率高于肝硬化组的阳性率,AFP、AFU和#2-MG三项指标联合检测阳性率明显高于各指标单独检测的阳性率(P<0.01)。结论 AFP、AFU和#2-MG联合检测可显著提高原发性肝癌诊断的阳性率,对原发性肝癌的早期诊断和及时治疗具有重要的临床应用价值。
Objective To investigate the value of combined detection of alpha-fetoprotein (AFP), α-L-fucosidase (AFU), and #2-microglobulin (#2-MG) in the diagnosis of primary liver cancer. Methods The levels of serum AFP, AFU, and #2-MG in 78 patients with primary liver cancer, 45 patients with liver cirrhosis, and 50 healthy subjects were detected by electrochemiluminescence, velocity and immuno-turbidimetric assays, respectively. Results The concentrations of AFP, AFU, and #2-MG in the serum of patients with primary liver cancer were higher than those in the cirrhosis group and the normal control group (P<0.01), and AFP, AFU, and #2- in the primary liver cancer group. The positive rate of MG was higher than that of cirrhosis group. The positive rate of combined detection of AFP, AFU, and #2-MG was significantly higher than the positive rate of each indicator alone (P<0.01). Conclusion The combined detection of AFP, AFU and #2-MG can significantly increase the positive rate of diagnosis of primary liver cancer. It has important clinical application value for the early diagnosis and timely treatment of primary liver cancer.